Pub. Date : 2019
PMID : 31338007
21 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | However, it is unknown whether DON stimulates IL-1beta expression through the activation of the nuclear factor-kappaB (NF-kappaB) pathway and the ACS/NLRP3 inflammasome. | deoxynivalenol | interleukin 1 beta | Mus musculus |
| 2 | DON also upregulated IL-1beta expression from between 0.5 h and 6 h after treatment, and enhanced the nuclear localization of the NF-kappaB subunits, p50 and p65. | deoxynivalenol | interleukin 1 beta | Mus musculus |
| 3 | NF-kappaB inhibitors, pyrrolidinedithiocarbamate and PS1145, significantly suppressed the DON-induced IL-1beta expression, which indicated that DON increased IL-1beta expression through the activation of NF-kappaB. | deoxynivalenol | interleukin 1 beta | Mus musculus |
| 4 | NF-kappaB inhibitors, pyrrolidinedithiocarbamate and PS1145, significantly suppressed the DON-induced IL-1beta expression, which indicated that DON increased IL-1beta expression through the activation of NF-kappaB. | deoxynivalenol | interleukin 1 beta | Mus musculus |
| 5 | NF-kappaB inhibitors, pyrrolidinedithiocarbamate and PS1145, significantly suppressed the DON-induced IL-1beta expression, which indicated that DON increased IL-1beta expression through the activation of NF-kappaB. | deoxynivalenol | interleukin 1 beta | Mus musculus |
| 6 | NF-kappaB inhibitors, pyrrolidinedithiocarbamate and PS1145, significantly suppressed the DON-induced IL-1beta expression, which indicated that DON increased IL-1beta expression through the activation of NF-kappaB. | deoxynivalenol | interleukin 1 beta | Mus musculus |
| 7 | In addition, marked secretion of IL-1beta protein occurred in the presence of DON at 24 h, and a caspase-1 inhibitor suppressed DON-mediated IL-1beta secretion, which suggested that caspase-1 induced the cleavage of pro-IL-1beta to lead the secretion of its active form. | deoxynivalenol | interleukin 1 beta | Mus musculus |
| 8 | In addition, marked secretion of IL-1beta protein occurred in the presence of DON at 24 h, and a caspase-1 inhibitor suppressed DON-mediated IL-1beta secretion, which suggested that caspase-1 induced the cleavage of pro-IL-1beta to lead the secretion of its active form. | deoxynivalenol | interleukin 1 beta | Mus musculus |
| 9 | In addition, marked secretion of IL-1beta protein occurred in the presence of DON at 24 h, and a caspase-1 inhibitor suppressed DON-mediated IL-1beta secretion, which suggested that caspase-1 induced the cleavage of pro-IL-1beta to lead the secretion of its active form. | deoxynivalenol | interleukin 1 beta | Mus musculus |
| 10 | In addition, marked secretion of IL-1beta protein occurred in the presence of DON at 24 h, and a caspase-1 inhibitor suppressed DON-mediated IL-1beta secretion, which suggested that caspase-1 induced the cleavage of pro-IL-1beta to lead the secretion of its active form. | deoxynivalenol | interleukin 1 beta | Mus musculus |
| 11 | Thus, components of the inflammasome, such as ASC and NLRP3, significantly increased by DON treatment; in addition, the knockdown of ASC and NLRP3 markedly downregulated DON-induced IL-1beta secretion, but not IL-1beta gene expression, which indicated that DON promoted IL-1beta secretion through the ASC/NLRP3 inflammasome. | deoxynivalenol | interleukin 1 beta | Mus musculus |
| 12 | Thus, components of the inflammasome, such as ASC and NLRP3, significantly increased by DON treatment; in addition, the knockdown of ASC and NLRP3 markedly downregulated DON-induced IL-1beta secretion, but not IL-1beta gene expression, which indicated that DON promoted IL-1beta secretion through the ASC/NLRP3 inflammasome. | deoxynivalenol | interleukin 1 beta | Mus musculus |
| 13 | Thus, components of the inflammasome, such as ASC and NLRP3, significantly increased by DON treatment; in addition, the knockdown of ASC and NLRP3 markedly downregulated DON-induced IL-1beta secretion, but not IL-1beta gene expression, which indicated that DON promoted IL-1beta secretion through the ASC/NLRP3 inflammasome. | deoxynivalenol | interleukin 1 beta | Mus musculus |
| 14 | Thus, components of the inflammasome, such as ASC and NLRP3, significantly increased by DON treatment; in addition, the knockdown of ASC and NLRP3 markedly downregulated DON-induced IL-1beta secretion, but not IL-1beta gene expression, which indicated that DON promoted IL-1beta secretion through the ASC/NLRP3 inflammasome. | deoxynivalenol | interleukin 1 beta | Mus musculus |
| 15 | Thus, components of the inflammasome, such as ASC and NLRP3, significantly increased by DON treatment; in addition, the knockdown of ASC and NLRP3 markedly downregulated DON-induced IL-1beta secretion, but not IL-1beta gene expression, which indicated that DON promoted IL-1beta secretion through the ASC/NLRP3 inflammasome. | deoxynivalenol | interleukin 1 beta | Mus musculus |
| 16 | Thus, components of the inflammasome, such as ASC and NLRP3, significantly increased by DON treatment; in addition, the knockdown of ASC and NLRP3 markedly downregulated DON-induced IL-1beta secretion, but not IL-1beta gene expression, which indicated that DON promoted IL-1beta secretion through the ASC/NLRP3 inflammasome. | deoxynivalenol | interleukin 1 beta | Mus musculus |
| 17 | Thus, components of the inflammasome, such as ASC and NLRP3, significantly increased by DON treatment; in addition, the knockdown of ASC and NLRP3 markedly downregulated DON-induced IL-1beta secretion, but not IL-1beta gene expression, which indicated that DON promoted IL-1beta secretion through the ASC/NLRP3 inflammasome. | deoxynivalenol | interleukin 1 beta | Mus musculus |
| 18 | Thus, components of the inflammasome, such as ASC and NLRP3, significantly increased by DON treatment; in addition, the knockdown of ASC and NLRP3 markedly downregulated DON-induced IL-1beta secretion, but not IL-1beta gene expression, which indicated that DON promoted IL-1beta secretion through the ASC/NLRP3 inflammasome. | deoxynivalenol | interleukin 1 beta | Mus musculus |
| 19 | Thus, components of the inflammasome, such as ASC and NLRP3, significantly increased by DON treatment; in addition, the knockdown of ASC and NLRP3 markedly downregulated DON-induced IL-1beta secretion, but not IL-1beta gene expression, which indicated that DON promoted IL-1beta secretion through the ASC/NLRP3 inflammasome. | deoxynivalenol | interleukin 1 beta | Mus musculus |
| 20 | Collectively, the data suggested that DON induced IL-1beta expression in BV2 microglial cells through the activation of the NF-kappaB signaling pathway and the subsequent upregulation of the ASC/NLRP3 inflammasome. | deoxynivalenol | interleukin 1 beta | Mus musculus |
| 21 | Therefore, DON may induce inflammatory diseases or disorders by activating IL-1beta expression. | deoxynivalenol | interleukin 1 beta | Mus musculus |